Sartorius Stedim Biotech (SDMHF) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the Sartorius and Sartorius Steeling Biotech conference call and live webcast on Q1 2026. I'm Moritz, your call's call operator. I would like to remind you that all participants will be in a listen-only mode and the conference has been recorded. A replay will be available shortly after the call. The presentation will be followed by a question and answer session. You can register for questions at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. I would now like to turn the conference over to Petra Müller, Head of Investor Relations of Sartorius. Please go ahead. Thank you. Hello, and a warm welcome also from my side. I'm joined today by our CEO, Michael Grossner, by Florian Funk, our CFO, by René Faber, head of the Bioprocessing Division and CEO of Sertori Still in Biotech, and by Alexandra Gatzemeier, head of our LPS Division. As always, we will start with prepared remarks, followed by the Q&A session. As the call is scheduled to one hour, please limit your questions to one so that as many participants as possible can take part. Please note that management comments during this call will include forward-looking statements that involve risks and uncertainties, For discussion of risk factors, I encourage you to review the safe harbor statement contained in today's press release and the presentation. And with that, I'm going to hand over to Michael Sartorius. Michael, please go ahead. Thank you, Petra, and a very warm welcome from my side as well. We are happy with the start of 2026, which is again sort of a transition year. Before turning to the key messages for the quarter, I would like to briefly reflect on the str...